 "Bharat Biotech, Covaxin")
DCGI gives permission to Bharat Biotech for intranasal booster dose trials
India's drug regulator has given permission to Bharat Biotech to conduct phase-3 clinical trial for its intranasal Covid vaccine as booster dose on participants who have been previously inoculated with SARS-CoV 2 vaccines.
India is yet to approve the use of intranasal COVID-19 vaccine BBV154 developed by the Hyderabad-based company. Read more
India to export BrahMos missiles to Philippines, signs $374-mn deal
India got its first ever export order for BrahMos missiles on Friday when the Philippines' Defence Ministry signed $374 million contract with BrahMos Aerospace Private Limited to supply
